Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

Publication ,  Journal Article
Gupta, K; Hudgens, M; Corey, L; McElrath, MJ; Weinhold, K; Montefiori, DC; Gorse, GJ; Frey, SE; Keefer, MC; Evans, TG; Dolin, R; Schwartz, DH ...
Published in: J Acquir Immune Defic Syndr
March 1, 2002

To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in both high-risk and low-risk persons and to evaluate variations in dosing schedule, we conducted a multicenter, randomized, double-blind trial of this vector in combination with recombinant subunit gp120 in 150 HIV-1-seronegative volunteers. The high-titered ALVAC vaccine was well tolerated; adverse events were minimal and not influenced by dosing. At day 728, the cumulative probability of a cytotoxic T-lymphocyte (CTL) response was 76% (95% confidence interval [CI]: 64%-89%) among volunteers receiving vaccine, and the net amount attributable to vaccination was 50% (CI: 16%; 74%). The net probability of a repeated positive CTL response by day 728 was 50% (CI: 21%; 64%). There was a significant difference in CTL response at day 182 between volunteers who had received four doses versus three doses of vCP205 (42% vs. 24%, p =.052). The CTL response was similar in high-risk volunteers and vaccinia-naive volunteers compared with vaccinia-immune volunteers. Neutralizing antibody responses were detected in 95% of vaccinees at day 287, with higher geometric mean titers in recipients of sequential versus simultaneous dosing of the two vaccines and in vaccinia-naive volunteers. This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers.

Duke Scholars

Published In

J Acquir Immune Defic Syndr

DOI

ISSN

1525-4135

Publication Date

March 1, 2002

Volume

29

Issue

3

Start / End Page

254 / 261

Location

United States

Related Subject Headings

  • Virology
  • Vaccines, Synthetic
  • Vaccines, Combined
  • T-Lymphocytes, Cytotoxic
  • Recombinant Proteins
  • Neutralization Tests
  • Male
  • Immunization Schedule
  • Humans
  • HIV-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gupta, K., Hudgens, M., Corey, L., McElrath, M. J., Weinhold, K., Montefiori, D. C., … AIDS Vaccine Evaluation Group, . (2002). Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr, 29(3), 254–261. https://doi.org/10.1097/00126334-200203010-00005
Gupta, Kalpana, Michael Hudgens, Lawrence Corey, M Juliana McElrath, Kent Weinhold, David C. Montefiori, Geoffrey J. Gorse, et al. “Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.J Acquir Immune Defic Syndr 29, no. 3 (March 1, 2002): 254–61. https://doi.org/10.1097/00126334-200203010-00005.
Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254–61.
Gupta, Kalpana, et al. “Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.J Acquir Immune Defic Syndr, vol. 29, no. 3, Mar. 2002, pp. 254–61. Pubmed, doi:10.1097/00126334-200203010-00005.
Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P, AIDS Vaccine Evaluation Group. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254–261.

Published In

J Acquir Immune Defic Syndr

DOI

ISSN

1525-4135

Publication Date

March 1, 2002

Volume

29

Issue

3

Start / End Page

254 / 261

Location

United States

Related Subject Headings

  • Virology
  • Vaccines, Synthetic
  • Vaccines, Combined
  • T-Lymphocytes, Cytotoxic
  • Recombinant Proteins
  • Neutralization Tests
  • Male
  • Immunization Schedule
  • Humans
  • HIV-1